T. Karamfilov et al., Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosisby dose increase, ARCH DERMAT, 136(4), 2000, pp. 487-490
Background: Primary focal hyperhidrosis is a common condition that gives ri
se to functional and emotional problems and may disturb professional and so
cial life. Recently, low-dose intracutaneous injections of botulinum toxin
A have been shown to induce a temporary anhidrosis, with relapses occurring
usually after 4 to 6 months.
Objective: To evaluate the short- and long-term effective-ess and possible
adverse effects of high-dose botulinum toxin therapy in the treatment of ax
illary hyperhidrosis.
Design: III an open study, patients with focal hyperhidrosis were treated w
ith intracutaneous injections of botulinum toxin A (Botox; Allergan Inc, Ir
vine, Calif). A total dose of 200 U of botulinum toxin A was used once per
axilla. Patients were observed for up to 15 months.
Settings: University medical center.
Patients: Twenty-four patients with axillary hyperhidrosis were treated. Th
eir ages ranged from 19 to 58 years (mean +/- SD, 34.8 +/- 12.4 years).
Main Outcome Measures: Reduction of sweating as assessed by the Minor iodin
e-starch test and planimetry of hyperhidrotic areas. Patients were intervie
wed at the end of follow-up about their satisfaction with this treatment.
Results: Within 6 days, all patients reported cessation of excessive sweati
ng. The mean +/- SD area of excessive sweating identified by the Minor iodi
ne-starch test decreased from 19.27 +/- 11.95 cm(2) to 0.25 +/- 0.61 cm(2)
(P < .001). The mean follow-up was 10.0 +/- 2.8 months (range, 5-15 months)
. Four patients (17%) reported a return of axillary hyperhidrosis after 7 t
o 10 months. All patients who experienced relapse showed an excellent respo
nse to a second treatment. The only adverse effects reported were temporary
pain and burning during the injections. No muscular weakness, insensitivit
y, or systemic reactions were observed.
Conclusions: High-dose botulinum toxin A seems to be as safe as low-dose bo
tulinum toxin A in the treatment of axillary hyperhidrosis. The preliminary
data suggest a lower rate of relapse.